N,N-dimethyltryptamine (DMT) is a serotonergic psychedelic that produces short-lived peak effects when administered intravenously as a bolus dose. Initial trials suggested therapeutic effects of DMT in depressive disorders. However, systematic data on dose-dependent pharmacokinetics and acute effects of intravenous bolus DMT administration are currently lacking. We used a double-blind,...
To our knowledge, this is the first fMRI characterization of 5-MeO-DMT in any species, and it reveals a previously unreported sex difference in psychedelic response. The rapid onset and brief duration of peak effects align with 5-MeO-DMT's unique pharmacological profile and clinical reports.
PsychedelicsMarch 1, 2026A.m Ortiz Bernal, C L Raison, A.m Vargas Prieto et al.
5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) is a potent, short-acting psychedelic compound found in several South American plant species and in the glandular secretions of Incilius alvarius, a toad native to the Sonoran Desert. While plant-based snuff preparations containing 5-MeO-DMT have documented use in Indigenous Caribbean and South American contexts, recent claims that toad-derived...
Results confirmed the safety profile of BPL-003 in a TRD population. A rapid and sustained reduction in MADRS score was observed over 12 weeks, suggesting BPL-003 could be beneficial in TRD, warranting investigation in larger controlled trials.
Bufotenin (also spelt as bufotenine) and its methylated derivative, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychedelics that are found in many plants but also excreted by some species of toads. The compounds are regulated differently around the world, and although used in traditional medicine, 20th-century prohibition culture has slowed research into their utility for...
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics as breakthrough therapies for mental disorders. Psychedelics can influence cognitive and emotional processes, showing solid therapeutic potential, particularly in treatment-resistant psychiatric disorders. Amongst the most promising compounds,...
Summarizes preclinical and clinical evidence on ayahuasca—a traditional Amazonian brew combining N, N-Dimethyltryptamine (DMT) and β-carbolines—in treating depression, anxiety, post-traumatic stress disorder, substance use, eating, and personality disorders. Preclinical work shows enhanced neuroplasticity, reduced inflammation, and oxidative stress. Human neuroimaging reveals decreased default...
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.
We carried out a systematic review of modern-era (1990-2025) placebo-controlled studies assessing the acute and post-acute effects of lysergic acid diethylamide, dimethyltryptamine and psilocybin on cognitive and psychological functions. From February 28 to March 19, 2025, PubMed and APA PsychINFO were systematically searched for placebo-controlled studies examining the influence of...